Free Trial

Enliven Therapeutics Q4 2023 Earnings Report

Enliven Therapeutics logo
$22.00 +0.53 (+2.47%)
As of 04:00 PM Eastern

Enliven Therapeutics EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.56
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Enliven Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enliven Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Enliven Therapeutics Earnings Headlines

Enliven Therapeutics: Still Too Early To Pay This Much
Enliven's Early Data Stands Out From Peers
2025: Crypto Opportunities You Can’t Afford to Miss
Cryptocurrencies are once again gaining incredible momentum, and savvy investors are positioning themselves to capitalize on this surge in 2025. The question is—will you be among them? With groundbreaking advancements and increasing institutional adoption on the horizon, there's never been a better time to explore the potential gains in crypto. What’s Fueling the Crypto Comeback?
See More Enliven Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email.

About Enliven Therapeutics

Enliven Therapeutics (NASDAQ:ELVN), a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

View Enliven Therapeutics Profile

More Earnings Resources from MarketBeat